Donovan Joanne M. 4
4 · Edgewise Therapeutics, Inc. · Filed May 3, 2023
Insider Transaction Report
Form 4
Transactions
- Exercise/Conversion
Common Stock
2023-05-01+10,416→ 13,214 total - Sale
Common Stock
2023-05-02$8.90/sh−3,254$28,977→ 9,960 total - Exercise/Conversion
Restricted Stock Units
2023-05-01−10,416→ 20,834 totalExercise: $0.00Exp: 2032-05-01→ Common Stock (10,416 underlying)
Footnotes (4)
- [F1]Includes 1,392 shares purchased on May 15, 2022 and 1,406 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F2]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.